A Phase I, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, PK and Antitumor Activities of the MEK Inhibitor CS3006 in Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 29 Jul 2019
Price : $35 *
At a glance
- Drugs CS-3006 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors CStone Pharmaceuticals
- 29 Jul 2019 Last checked against ClinicalTrials.gov.
- 25 Jul 2019 Planned number of patients changed from 60 to 36.
- 25 Jul 2019 Planned primary completion date changed from 1 Mar 2020 to 1 May 2020.